Boehringer settles Pradaxa suits

Share this article:

Boehringer Ingelheim is settling around 4,000 Pradaxa lawsuits for $650 million. The company announced Wednesday that it had reached a “comprehensive settlement of state and federal cases” and that the decision “enables Boehringer Ingelheim to focus solely on its mission of improving patients' lives.”

Bloomberg reports this breaks down to around $162,500 per suit and that the agreement comes just months before the first of several lawsuits were expected to begin in September.

The lawsuits center around claims that there was no antidote to prevent bleeding-related deaths among those who took the blood thinner.

BI announced earlier this month that it was going to start testing the antidote idarucizumab among Pradaxa patients.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.